Why Gynaecological Cancers Are Some of Pharma’s Most Important Challenges

September is Gynecologic Cancer Awareness Month, but awareness alone does not address the complexity of the diseases involved. Across cervical, ovarian, uterine, vaginal, and vulvar cancers, pharma faces a combination of changing disease patterns, unequal access to care, difficult diagnosis, and increasingly complex tumour biology.

The challenge is identifying where innovation can make the greatest difference, developing therapies for increasingly heterogeneous diseases, and ensuring those advances reach the patients who need them.

Image

The Global Burden of Gynaecological Cancers

The global burden of gynaecological cancers is far more complicated than a single cancer incidence or mortality figure suggests.

A 2025 BMC Women’s Health study analysed Global Burden of Disease 2021 data across countries and regions, examining trends from 1990 to 2021 and projecting future trajectories.

The meta-analysis found different burden patterns across cancer types: Age-standardised incidence and mortality declined for ovarian and cervical cancers over the study period, while uterine cancer showed a different trajectory, with incidence increasing even as age-standardised mortality and disability-adjusted life years declined. 

That’s an important divergence for drug development.

A changing disease burden requires differentiated developmental strategies. Prevention may be the highest-impact intervention for one cancer, earlier detection for another, and molecularly targeted treatment for a separate cancer type.

However, the burden across all gynaecological cancers remains substantial.

A 2025 review in the International Journal of Gynecology & Obstetrics estimated that approximately 1.4 million women were diagnosed with a gynaecological cancer and more than 600,000 died from these diseases in 2022.

There is also a hugely disproportionate burden carried by low- and middle-income countries (LMICs). 

The challenge is therefore not one market or one therapeutic problem. It is a collection of diseases with different biological, clinical, and health-system challenges.

The Drug Innovation Gap Is Accurately an Access Gap

One of the most uncomfortable realities in cancer innovation is that scientific progress does not automatically produce equitable outcomes.

Limited healthcare access, inadequate cervical screening, underdeveloped infrastructure, socioeconomic barriers, and shortages of trained specialists and advanced diagnostics as important drivers of disparities in gynaecological cancer outcomes.

This creates a fundamental disconnect. A therapy cannot improve survival if a patient cannot access diagnosis. A diagnostic technology cannot transform outcomes without an appropriate referral pathway. And prevention cannot work at population scale without delivery infrastructure.

Cervical cancer demonstrates the issue particularly clearly.

Unlike many cancers, cervical cancer has an established prevention and elimination framework. The World Health Organisation (WHO) global strategy sets 2030 targets of vaccinating 90% of girls against HPV by age 15, screening 70% of women with a high-performance test by ages 35 and 45, and treating 90% of women with precancer or invasive cancer. 

Image

Yet the existence of effective interventions does not mean they are universally available.

The WHO’s latest cervical cancer initiatives continue to focus on bringing screening closer to communities, strengthening referral pathways and closing treatment gaps. In 2026, the WHO also issued updated guidance on HPV DNA genotyping, highlighting molecular risk stratification as a way to improve screening and clinical management. 

This should help change how pharma R&D teams should think about innovation.

The next breakthrough may not always be a new molecule. It could be a better diagnostic, a simpler screening pathway, a more deployable technology, or an integrated model that connects prevention to treatment.

Read Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Reimagine AI-driven Drug Discovery with Pharma Superintelligence

Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.

Ovarian Cancer Shows Why Biology Still Wins

If cervical cancer demonstrates the challenge of translating known interventions into population-level impact, ovarian cancer demonstrates a different problem.

The biology itself is extraordinarily complex.

A major review in Nature Reviews Clinical Oncology describes ovarian carcinoma as heterogeneous at molecular, cellular, and anatomical levels, with variation occurring between patients, within individual patients and across different areas and stages of a tumour.

This heterogeneity influences treatment response and contributes to both inherent and acquired drug resistance. 

That has profound implications for drug development.

Historically, ovarian carcinoma could be approached as a relatively broad disease category. Increasing molecular understanding is changing that.

Different subtypes have distinct molecular landscapes, while interactions between tumour cells and the surrounding tumour microenvironment can influence disease evolution and response to therapy.

The result is a familiar problem across precision oncology that the more biology we uncover, the less useful a single disease label becomes.

That creates a chain of challenges:

Disease heterogeneity → biomarker complexity → patient stratification → clinical trial design → treatment response → resistance → new therapeutic strategies

It also raises the value of technologies that can characterise disease more precisely.

The future of ovarian cancer treatment therefore depends not only on discovering new therapeutic mechanisms, but on understanding which biological mechanism is relevant to which patient, at which point in the disease journey.

Precision Medicine Increases Complexity of Drug Development

Precision medicine promises more effective treatment by matching therapies to disease biology. But it also introduces a paradox.

The better we become at dividing cancers into molecularly meaningful subgroups, the harder it can become to develop and test treatments across sufficiently large patient populations.

That has implications for clinical development.

Biomarker-driven clinical development may require more sophisticated eligibility criteria, while smaller molecularly defined populations can make recruitment harder.

As a result, diagnostic testing becomes more important.

And treatment decisions increasingly depend on data generated across multiple stages of the patient journey.

The challenge is therefore identifying the right patient, at the right time, using sufficiently reliable evidence.

This is where drug discovery, diagnostics, clinical development, and data infrastructure increasingly converge.

It is also where artificial intelligence could be most important. AI may support biomarker discovery, image analysis, molecular classification, patient identification, and trial recruitment.

But technology is only valuable when it improves the quality, speed or accessibility of decisions across the care pathway.

The objective should be better women’s cancer outcomes enabled by better data and better decisions.

The Next Breakthrough Must Close More Than One Gap

Gynaecological cancers therefore present pharma with a challenge that cannot be solved by one therapeutic modality.

• There is a prevention gap, particularly where HPV vaccination and cervical screening remain difficult to deliver.
• There is a diagnostic gap, where disease may be identified too late or where advanced molecular characterisation is unavailable.
• There is a therapeutic gap, where aggressive or heterogeneous cancers develop resistance despite increasingly sophisticated treatment options.
• And there is an access gap, where advances made in high-income healthcare systems do not automatically reach populations in resource-constrained settings.

The challenge is to address these gaps as connected problems.

That means investing not only in new medicines, but also in biomarkers, companion diagnostics, prevention technologies, precision medicine, clinical trial infrastructure, and evidence generation.

It means designing drug development programmes around increasingly diverse patient populations rather than assuming that one disease label represents one biological reality.

And it means recognising that innovation has little value if the healthcare system cannot deliver it.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Image

Pharma Must Meet the Challenge of Beating Gynaecological Cancers

U.S. September’s Gynecologic Cancer Awareness Month is a reminder of the burden of the four gynaecological cancers. For pharma, however, the more important question is what comes next.

The next generation of gynaecological cancer innovation will be judged not simply by how many therapies reach the market, but by whether those therapies enable earlier detection, more precise treatment and better outcomes across diverse populations who need them.

For Pharmatica, we realise the convergence of drug discovery, precision medicine, diagnostics, clinical development, data, and medicines access may ultimately determine how much progress the next decade delivers.

Pharmatica: Insight. Connection. Impact.

Image